Edwards Lifesciences Corp
EW: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| v#k | LOCK|!#%v | LOCK|mm^>?d% |
Edwards Lifesciences Earnings: Indication Expansion to Asymptomatic Should Support TAVR Growth
Edwards posted second-quarter earnings that featured 9% top-line and 16% adjusted bottom-line growth, fueled by an acceleration in transcatheter aortic valve replacement, or TAVR, along with strong adoption of transcatheter mitral and tricuspid devices.
